Get the Stockscreener App
129.58
1.88%
-2.48
After Hours:
129.06
-0.52
-0.40%
Overview
News
Price History
Option Chain
Financials
Why GILD Down?
Discussions
Forecast
Stock Split
Dividend History
Gilead Sciences Inc stock is traded at $129.58, with a volume of 6.64M.
It is down -1.88% in the last 24 hours and down -7.29% over the past month.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$132.06
Open:
$132.27
24h Volume:
6.64M
Relative Volume:
1.07
Market Cap:
$160.88B
Revenue:
$29.79B
Net Income/Loss:
$9.22B
P/E Ratio:
17.63
EPS:
7.3494
Net Cash Flow:
$10.23B
1W Performance:
-1.33%
1M Performance:
-7.29%
6M Performance:
+3.65%
1Y Performance:
+29.14%
1-Day Range:
$129.09
$132.81
1-Week Range:
$129.09
$137.50
52-Week Range:
$100.23
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Name
Gilead Sciences Inc
Sector
Industry
Phone
(650) 574-3000
Address
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, NVS, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
129.58 | 163.96B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-26 | Initiated | Jefferies | Buy |
| Feb-20-26 | Initiated | Barclays | Equal Weight |
| Feb-11-26 | Reiterated | Needham | Buy |
| Jan-07-26 | Resumed | UBS | Buy |
| Nov-24-25 | Resumed | Truist | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Aug-19-25 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Aug-08-25 | Upgrade | Truist | Hold → Buy |
| Jul-25-25 | Upgrade | Needham | Hold → Buy |
| Apr-22-25 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-04-25 | Reiterated | Oppenheimer | Outperform |
| Feb-18-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-13-25 | Upgrade | DZ Bank | Hold → Buy |
| Jan-10-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-14-24 | Initiated | Citigroup | Buy |
| Nov-08-24 | Downgrade | Maxim Group | Buy → Hold |
| Oct-21-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Oct-07-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jul-08-24 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-24 | Reiterated | Maxim Group | Buy |
| Apr-24-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Feb-22-24 | Downgrade | Truist | Buy → Hold |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Sep-08-23 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-06-23 | Initiated | HSBC Securities | Reduce |
| Jul-24-23 | Reiterated | Barclays | Equal Weight |
| May-16-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-28-23 | Resumed | Piper Sandler | Overweight |
| Jan-03-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Dec-13-22 | Resumed | BofA Securities | Neutral |
| Dec-09-22 | Downgrade | DZ Bank | Buy → Hold |
| Oct-31-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-28-22 | Reiterated | BMO Capital Markets | Market Perform |
| Oct-28-22 | Reiterated | Cowen | Outperform |
| Oct-28-22 | Reiterated | JP Morgan | Overweight |
| Oct-28-22 | Reiterated | Jefferies | Buy |
| Oct-28-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-28-22 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-28-22 | Upgrade | Truist | Hold → Buy |
| Oct-28-22 | Reiterated | Wells Fargo | Equal Weight |
| Oct-04-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Feb-28-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Feb-02-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-02-22 | Reiterated | BofA Securities | Neutral |
| Feb-02-22 | Reiterated | RBC Capital Mkts | Outperform |
| Feb-02-22 | Reiterated | Truist | Hold |
| Feb-02-22 | Reiterated | Wells Fargo | Equal Weight |
| Jan-28-22 | Upgrade | Argus | Hold → Buy |
| Jan-06-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Dec-06-21 | Initiated | Goldman | Neutral |
| Nov-19-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-19-21 | Resumed | Piper Sandler | Neutral |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jul-30-21 | Reiterated | BMO Capital Markets | Market Perform |
| Jul-30-21 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-01-21 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-30-21 | Upgrade | Redburn | Neutral → Buy |
| Jan-19-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-03-20 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-28-20 | Initiated | UBS | Neutral |
| Sep-30-20 | Resumed | Jefferies | Buy |
| Sep-15-20 | Upgrade | Maxim Group | Hold → Buy |
| Jul-31-20 | Reiterated | Credit Suisse | Neutral |
| Jul-31-20 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-31-20 | Reiterated | Piper Sandler | Overweight |
| Jul-31-20 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-31-20 | Reiterated | SunTrust | Hold |
| Jul-31-20 | Reiterated | Wells Fargo | Equal Weight |
| Jul-20-20 | Upgrade | Credit Suisse | Underperform → Neutral |
| Jun-03-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-26-20 | Upgrade | SunTrust | Sell → Hold |
| May-01-20 | Downgrade | JP Morgan | Overweight → Neutral |
| May-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-20 | Downgrade | SunTrust | Hold → Sell |
| Apr-27-20 | Downgrade | UBS | Buy → Neutral |
| Apr-20-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Apr-20-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
View All
Gilead Sciences Inc Stock (GILD) Latest News
Gilead Sciences Inc stock (US3755581036): Insider share sale plans draw attention to valuation and p - AD HOC NEWS
Gilead Sciences, Inc. $GILD Shares Acquired by Commerzbank Aktiengesellschaft FI - MarketBeat
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Officer files Form 144 — GILD (NASDAQ: GILD) lists 25,000-share option sale - Stock Titan
Latham & Watkins Advises on Gilead Sciences’ US$3 Billion Senior Unsecured Notes Offering - Latham & Watkins LLP
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Insulet (PODD) and Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences prices $3B multi-tranche senior notes offering - MSN
Gilead Sciences Prices $3 Billion Debt Offering - Moomoo
Gilead Sciences, Inc. $GILD Shares Sold by Conning Inc. - MarketBeat
Atria Investments Inc Acquires 12,906 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Arbejdsmarkedets Tillaegspension Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD is AustralianSuper Pty Ltd's 9th Largest Position - MarketBeat
Ameritas Advisory Services LLC Increases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Prices $3B Senior Unsecured Notes Offerin - GuruFocus
Gilead Prices $3 Billion of Senior Unsecured Notes - New Castle News
Gilead Sciences stock (US3755581036): Q1 earnings, FDA timing and investor focus - AD HOC NEWS
Gilead Sciences Just Told Investors What to Watch Before December 23. Here’s What the Data Says About GILD Stock. - TIKR.com
Gilead Sciences launches bond offering after acquisition spreeBloomberg By Investing.com - Investing.com Canada
Gilead Sciences (GILD) files for multi‑tranche senior unsecured note offering - Stock Titan
Oppenheimer Remains a Buy on Gilead Sciences (GILD) - The Globe and Mail
Gilead Sciences’s Q1 Earnings Call: Our Top 5 Analyst Questions - The Globe and Mail
Gilead to Present New Data Advancing Care in PBC and Viral Hepatitis at EASL 2026 - BioSpace
Bay Area biotech giant Gilead to lay off 108 workers in Redwood City - MSN
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Is It Worth Investing in Gilead (GILD) Based on Wall Street's Bullish Views? - Yahoo Finance
Gilead’s Transition Into A Long-Duration Biotech Platform (NASDAQ:GILD) - Seeking Alpha
Gilead to present liver disease data at EASL conference By Investing.com - Investing.com Canada
Oppenheimer Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $165 - Moomoo
Gilead Sciences, Inc. $GILD Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - MarketBeat
Nurix Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire Inc.
Trek Financial LLC Purchases 13,041 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
RBC Capital Remains a Hold on Gilead Sciences (GILD) - The Globe and Mail
Bailard Inc. Has $90.10 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook - Yahoo Finance
Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs - Insider Monkey
Gilead Sciences (NASDAQ:GILD) Price Target Lowered to $167.00 at Rothschild & Co Redburn - MarketBeat
RBC Capital maintains Gilead Sciences stock rating on UC drug data - Investing.com
Gilead Sciences stock (US3755581036): Biotech leader navigates HIV and oncology markets - AD HOC NEWS
Gilead Sciences, Inc. (NASDAQ:GILD) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Swiss Life Asset Management Ltd Reduces Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Reports Strong HIV Growth, Raises Outlook for 2026 - Value The Markets
Kepler Cheuvreux Suisse SA Acquires New Position in Gilead Sciences, Inc. $GILD - MarketBeat
Securian Asset Management Inc. Has $4.14 Million Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Stock Analysis: A 20% Upside Potential Amid Robust Growth In Healthcare - DirectorsTalk Interviews
Gilead Sciences, Inc. $GILD Shares Acquired by ABN AMRO Bank N.V. - MarketBeat
NewEdge Wealth LLC Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
JSF Financial LLC Takes $1.25 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences Beat Q1 2026 Earnings and Raised Guidance. Why Is GILD Stock Still Down 17%? - TIKR.com
Stronger HIV Pipeline And Acquisition Charges Might Change The Case For Investing In Gilead Sciences (GILD) - Yahoo Finance
Morgan Stanley Issues Pessimistic Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - MarketBeat
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $157 to $177 - Moomoo
Gilead Sciences Inc Stock (GILD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):